NCT07217119 · OUTCOME
DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · Source last updated 2026-06-25
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure COUNT_OF_PARTICIPANTS
Unit Participants
Interval / dispersion Not reported
Time frame Baseline (Day 1) and up to approximately 281 weeks. What was measured Blood samples were collected for evaluation of hematology parameters including Anemia, Hemoglobin increased (HbI), Lymphocyte count decreased (LyD), Lymphocytes count increased (LyI), Neutrophils count decreased (NeuD), Platelet count decreased (PD), Leukocytosis (LC) and White blood cell decreased (WBCD). The laboratory parameters were graded according to CTCAE v5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment.
Analysis population: Safety population
Groups in this outcome 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Reported measurements Anemia, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
Anemia, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
Anemia, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
Anemia, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
HbI, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
HbI, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
HbI, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
HbI, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LyD, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
LyD, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 2 Not reported Not reported Not reported Not reported
LyD, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 4 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
LyD, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LyI, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LyI, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LyI, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LyI, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
NeuD, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
NeuD, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
NeuD, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
NeuD, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
PD, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 4 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 4 Not reported Not reported Not reported Not reported
PD, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
PD, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
PD, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LC, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LC, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LC, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
LC, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
WBCD, Increase to G1 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1 Not reported Not reported Not reported Not reported
WBCD, Increase to G2 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 2 Not reported Not reported Not reported Not reported
WBCD, Increase to G3 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
WBCD, Increase to G4 Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0 Not reported Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 Not reported Not reported Not reported Not reported
Complete source fields classes categories measurements
group Id OG000
value 1
group Id OG001
value 1
group Id OG002
value 0
title Anemia, Increase to G1 categories measurements
group Id OG000
value 0
group Id OG001
value 1
group Id OG002
value 0
title Anemia, Increase to G2 categories measurements
group Id OG000
value 2
group Id OG001
value 2
group Id OG002
value 1
title Anemia, Increase to G3 categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
title Anemia, Increase to G4 categories measurements
group Id OG000
value 0
group Id OG001
value 1
group Id OG002
value 0
title HbI, Increase to G1 categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
title HbI, Increase to G2 categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
title HbI, Increase to G3 categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
title HbI, Increase to G4 categories measurements
group Id OG000
value 1
group Id OG001
value 2
group Id OG002
value 1
title LyD, Increase to G1 categories measurements
group Id OG000
value 1
group Id OG001
value 1
group Id OG002
value 2
title LyD, Increase to G2 categories measurements
group Id OG000
value 2
group Id OG001
value 4
group Id OG002
value 1
title LyD, Increase to G3 categories measurements
group Id OG000
value 1
group Id OG001
value 0
group Id OG002
value 0
title LyD, Increase to G4 Show more (12 of 32) denoms counts
group Id OG000
value 9
group Id OG001
value 10
group Id OG002
value 6
units Participants
description Blood samples were collected for evaluation of hematology parameters including Anemia, Hemoglobin increased (HbI), Lymphocyte count decreased (LyD), Lymphocytes count increased (LyI), Neutrophils count decreased (NeuD), Platelet count decreased (PD), Leukocytosis (LC) and White blood cell decreased (WBCD). The laboratory parameters were graded according to CTCAE v5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. groups
description Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
id OG000
title 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
description Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
id OG001
title 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
description Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
id OG002
title 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab
param Type COUNT_OF_PARTICIPANTS
population Description Safety population
reporting Status POSTED
time Frame Baseline (Day 1) and up to approximately 281 weeks.
title DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline
type PRIMARY
unit Of Measure Participants Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle